| Biomarker ID | 1209 |
| PMID | 24046815 |
| Year | 2013 |
| Biomarker | RNASEL [R462Q variant: AA] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | Expressed in patients with High Risk of PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Interferon alpha/beta signaling, Senescence and autophagy, Interferon signaling, Immune system signaling by interferons, interleukins, prolactin, and growth hormones, Immune system |
| Experiment | High Risk with AA phenotype Vs High Risk with (AA and GA phenotype) |
| Type of Biomarker | Prognostic |
| Cohort | A total of 231 patients (histopathologically confirmed after abnormal serum PSA findings) were enrolled. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p≤ 0.001 |
| Method Used | Organic extraction procedure with phenol/chloroform/ isoamyl alcohol and proteinase K |
| Clinical | No |
| Remarks | High Risk was categorised as : Local stage with values ≥ T2c and [Gleason score > 7 orPSA > 20 ng/ml] |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |